检验

订阅

MedSci主页 / 所有栏目 / 检验

Clinica Chimica Acta：含有阿米替林和去甲三氟替林验证材料的可交换性-荷兰校准2.000项目框架内的一项研究

2019-11-23 MedSci MedSci原创

可交换性
关注

如果样品基质由可交换材料组成，则外部质量评估方案（EQAS）可以提供有关不同测量方法的准确性和可比性的重要信息。

如果样品基质由可交换材料组成，则外部质量评估方案（EQAS）可以提供有关不同测量方法的准确性和可比性的重要信息。 这项研究的目的是评估用于阿米替林和去甲替林的EQAS中材料的不同基质的可交换性。

本研究的目的是评估不同基质用研究人员制备，收集，合并了含阿米替林和去甲替林的能力测试材料（PTM）和患者样品，并分发给参与的实验室进行分析。 在这项研究中，对液体合并的人血清，冻干人血清和冻干牛血清中两种药物的低，中和高浓度进行了测试。 通过除以官方EQAS中报告的结果得出的实验室内平均SD（SDwl）的平均值，将PTM结果与患者血清回归线的测量偏差归一化。 可通行性决定限制设置为3 SDwl。

本研究共有10个实验室参与了这项研究，形成了45对实验室对。所有的矩阵类型都在可交换性决策极限之外提供了几个相对残差。与冻干的人和牛血清相比，这两种药物在人血清中相对残留的数量和大小都较低。

研究表明，阿米替林和去甲替林所用的PTM最好用人血清制备，尽管并非所有相对残基都在可交换性决定极限之内。

原始出处：

Karen Robijns，Niels W. Boone，Commutability of proficiency testing material containing amitriptyline and nortriptyline: A study within the framework of the Dutch Calibration 2.000 project

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849805, encodeId=09ca184980561, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Oct 10 01:47:00 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069571, encodeId=c69720695e153, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 10 01:47:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457322, encodeId=577e145e3222a, content=<a href='/topic/show?id=570e9e9186d' target=_blank style='color:#2F92EE;'>#阿米替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97918, encryptionId=570e9e9186d, topicName=阿米替林)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb845885644, createdName=zhyy90, createdTime=Mon Nov 25 12:47:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375731, encodeId=08e33e57312c, content=非常好的研究，受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 21:57:32 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-10-10 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849805, encodeId=09ca184980561, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Oct 10 01:47:00 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069571, encodeId=c69720695e153, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 10 01:47:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457322, encodeId=577e145e3222a, content=<a href='/topic/show?id=570e9e9186d' target=_blank style='color:#2F92EE;'>#阿米替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97918, encryptionId=570e9e9186d, topicName=阿米替林)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb845885644, createdName=zhyy90, createdTime=Mon Nov 25 12:47:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375731, encodeId=08e33e57312c, content=非常好的研究，受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 21:57:32 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-12-10 liye789132251

    #可交换性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849805, encodeId=09ca184980561, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Oct 10 01:47:00 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069571, encodeId=c69720695e153, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 10 01:47:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457322, encodeId=577e145e3222a, content=<a href='/topic/show?id=570e9e9186d' target=_blank style='color:#2F92EE;'>#阿米替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97918, encryptionId=570e9e9186d, topicName=阿米替林)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb845885644, createdName=zhyy90, createdTime=Mon Nov 25 12:47:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375731, encodeId=08e33e57312c, content=非常好的研究，受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 21:57:32 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-25 zhyy90

    #阿米替林#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1849805, encodeId=09ca184980561, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Oct 10 01:47:00 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069571, encodeId=c69720695e153, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 10 01:47:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457322, encodeId=577e145e3222a, content=<a href='/topic/show?id=570e9e9186d' target=_blank style='color:#2F92EE;'>#阿米替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97918, encryptionId=570e9e9186d, topicName=阿米替林)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb845885644, createdName=zhyy90, createdTime=Mon Nov 25 12:47:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375731, encodeId=08e33e57312c, content=非常好的研究，受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 21:57:32 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 14794e5bm67(暂无昵称)

    非常好的研究，受益良多

    0